The CONSORT statement checklist in allergen‐specific immunotherapy: a GA2LEN paper
Abstract
The methodology of randomized clinical trials is essential for the critical assessment and registration of therapeutic interventions. The CONSORT (Consolidated Standards of Reporting Trials) statement was developed to alleviate the problems arising from the inadequate reporting of randomized controlled trials. The present article reflects on the items that we believe should be included in the CONSORT checklist in the context of conducting and reporting trials in allergen‐specific immunotherapy. Only randomized, blinded (in particular blinding of patients, health care providers, and outcome assessors), placebo‐controlled Phase III studies in this article. Our analysis focuses on the definition of patients’ inclusion and exclusion criteria, allergen standardization, primary, secondary and exploratory outcomes, reporting of adverse events and analysis.Keywords
This publication has 45 references indexed in Scilit:
- Quality of randomised trials in COPDEuropean Respiratory Journal, 2009
- GA2LEN (Global Allergy and Asthma European Network) addresses the allergy and asthma ‘epidemic’Allergy, 2009
- Grading quality of evidence and strength of recommendations in clinical practice guidelinesAllergy, 2009
- The Regulatory System in Europe with Special Emphasis on Allergen ProductsInternational Archives of Allergy and Immunology, 2008
- Extending the CONSORT Statement to Randomized Trials of Nonpharmacologic Treatment: Explanation and ElaborationAnnals of Internal Medicine, 2008
- Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforceAllergy, 2007
- Spreading excellence in allergy and asthma: the GA2LEN (Global Allergy and Asthma European Network) projectAllergy, 2005
- The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trialsThe Lancet, 2001
- Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?The Lancet, 1998
- Improving the Quality of Reporting of Randomized Controlled TrialsJAMA, 1996